MicroCHIPS, Inc. Names Tamborlane to New Scientific Advisory Board
Published: Sep 25, 2008
BEDFORD, Mass., Sept. 24 /PRNewswire/ -- MicroCHIPS, Inc., a developer of novel intelligent implanted devices, has formed a scientific advisory board with Yale University endocrinologist and diabetes researcher William V. Tamborlane, M.D., FAAP, FACE, as its founding member.
The scientific advisory board will support MicroCHIPS in its development of next-generation biosensing and drug delivery devices to increase therapeutic control and effectiveness for people with diabetes, osteoporosis and other debilitating diseases. The company's lead program is a long-term implanted continuous glucose monitoring device using the company's patented microreservoir technologies.
Dr. Tamborlane is Professor and Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine. He has served on the FDA's Endocrine Advisory Board and on the National Board of Directors of the American Diabetes Association. He has published more than 445 original articles, chapters, and reviews in the area of diabetes. He holds a B.S. and an M.D. from Georgetown University.
"Dr. Tamborlane will provide unique insights into how our technology can help people with diabetes better manage glucose levels to improve overall health," said John Santini, President and CEO, MicroCHIPS. "The formation of our scientific advisory board represents an important milestone in the advancement of our diabetes program."
Dr. Tamborlane and others published the results of a landmark multicenter continuous glucose monitoring study in the New England Journal of Medicine earlier this month. In the study, funded by the Juvenile Diabetes Research Foundation, continuous glucose monitoring improved glycemic control in adults with Type 1 diabetes who incorporated the technology into their daily lives.
"Because the greatest improvements were seen in those patients who used the sensors more often, devices that can sense continuously for an extended period will represent a critical advancement," said Dr. Tamborlane. "The device that MicroCHIPS has under development holds great promise in this area."
MicroCHIPS is establishing its scientific advisory board in support of its diabetes program and will also add clinical expertise for its drug delivery program in osteoporosis. This program will leverage the technology platform to address delivery challenges that limit the treatment of osteoporosis, a disease that affects over 200 million people worldwide.
MicroCHIPS, Inc. is pioneering intelligent implanted devices designed to improve the health of millions of people with chronic conditions that require careful monitoring and precise therapy. Based on proprietary microreservoir technology first developed at MIT, MicroCHIPS' platform incorporates long-term implant technologies and wireless communications, as well as expertise in protein and peptide formulation for challenging delivery conditions.
MicroCHIPS' technologies are designed to transform electromechanical medical devices into highly tuned biochemical sensing and therapy systems. http://www.mchips.com.
CONTACT: Maggie A. Pax, Vice President, Business Development of
MicroCHIPS, Inc., +1-781-275-1445, ext. 220, email@example.com
Web site: http://www.mchips.com/